Evidence map›Paper›PMID 27595286›Full record

Trial reportBone marrow transplantation2017

Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

A Sirvent, P Auquier, C Oudin, Y Bertrand, S Bohrer, P Chastagner, M Poirée, J Kanold, S Thouvenin, Y Perel and 12 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 1 country.

A SirventDepartment of Pediatric Hematology and Oncology, University Hospital, Montpellier, France.
P AuquierResearch Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.
C OudinResearch Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.
Y BertrandDepartment of Pediatric Hematology and Oncology, University Hospital, Lyon, France.
S BohrerDepartment of Pediatric Hematology and Oncology, University Hospital, Montpellier, France.
P ChastagnerDepartment of Pediatric Hematology and Oncology, Hôpital d'Enfants de Brabois, Vandoeuvre Les Nancy, France.
M PoiréeDepartment of Pediatric Hematology and Oncology, University Hospital L'Archet, Nice, France.
J KanoldDepartment of Pediatric Hematology and Oncology, University Hospital, Clermont-Ferrand, France.
S ThouveninDepartment of Pediatric Hematology and Oncology, University Hospital, Saint Etienne, France.
Y PerelDepartment of Pediatric Hematology and Oncology, University Hospital, Bordeaux, France.
D PlantazDepartment of Pediatric Hematology and Oncology, University Hospital, Grenoble, France.
M-D TaboneDepartment of Pediatric Hematology and Oncology, Trousseau Hospital, Paris, France.
K YakoubenDepartment of Pediatric Hematology- Immunology, Robert Debré Hospital, and Paris Diderot University, Sorbonne Paris-Cité, Paris, France.
V GandemerDepartment of Pediatric Hematology and Oncology, University Hospital, Rennes, France.
P LutzDepartment of Pediatric Hematology-oncology, Hospital University, Strasbourg, France.
N SirventDepartment of Pediatric Hematology and Oncology, University Hospital, Montpellier, France.
C VercassonResearch Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.
J BerbisResearch Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.
H ChambostDepartment of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France.
G LevergerDepartment of Pediatric Hematology and Oncology, Trousseau Hospital, Paris, France.
A BaruchelDepartment of Pediatric Hematology- Immunology, Robert Debré Hospital, and Paris Diderot University, Sorbonne Paris-Cité, Paris, France.
G MichelResearch Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France.
Hôpital de la Timone · FRCentre Hospitalier Universitaire de Montpellier · FRAix-Marseille Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre de Recherche en Cancérologie de Lyon · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire de Rennes · FRCentre Hospitalier Universitaire de Saint-Étienne · FRDélégation Paris 7 · FRHôpital d'Enfants · FRInstitut d’Hématologie et d’Oncologie Pédiatrique · FRSorbonne Université · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on post-transplant iron overload (IO) are scarce in pediatrics. We conducted a prospective multicenter cohort study (Leucémie de l'Enfant et de l'Adolescent cohort) to determine the prevalence and risk factors of IO in 384 acute leukemia survivors transplanted during childhood. Prevalence of IO (ferritin level ⩾350 ng/mL) was 42.2% (95%CI 37.2-47.2%). Factors significantly associated with IO were: 1) in univariate analysis: older age at transplant (P<0.001), allogeneic versus autologous transplantation (P<0.001), radiation-based preparative regimen (P=0.035) and recent period of transplantation (P<0.001); 2) in multivariate analysis: older age at transplant in quartiles (Odds Ratio (OR)=7.64, 95% CI: 3.73-15.64 for age >12.7 years and OR=5.36, 95% CI: 2.63-10.95 for age from 8.2 to 12.7 years compared to age < 4.7 years), acute myeloid leukemia (OR=3.23, 95% CI: 1.47-7.13), allogeneic graft (OR=4.34, 95% CI: 2.07-9.12 for alternative donors and OR=2.53, 95% CI: 1.2-5.33 for siblings, compared to autologous graft) and radiation-based conditioning regimen (OR=2.45, 95% CI: 1.09-5.53). Graft-versus-host disease was an additional risk factor for allogeneic graft recipients. In conclusion, IO is a frequent complication in pediatric long-term survivors after transplantation for acute leukemia, more frequently observed in older children, those transplanted from alternative donors or with graft-versus-host disease.

Indexed as

Cancer SurvivorsHematopoietic Stem Cell TransplantationTransplantation ConditioningAge FactorsAllograftsChildFemaleFerritinsGraft vs Host DiseaseHumansIron OverloadLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaPrevalenceRisk FactorsFerritins

Identifiers

PMID27595286
OpenAlexW2517090332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.